{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:41:01Z","timestamp":1761183661547,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K16136"],"award-info":[{"award-number":["20K16136"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jphs.2022.05.004","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T11:23:03Z","timestamp":1652527383000},"page":"175-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Roles of IK,ACh for perpetuating atrial fibrillation: Effects of atrial-selective K+ channel inhibitor AVE0118 and class I drugs on the persistent atrial fibrillation canine model"],"prefix":"10.1016","volume":"149","author":[{"given":"Ryuichi","family":"Kambayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Izumi-Nakaseko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2022.05.004_bib1","doi-asserted-by":"crossref","first-page":"581837","DOI":"10.3389\/fphar.2020.581837","article-title":"Revisiting antiarrhythmic drug therapy for atrial fibrillation: reviewing lessons learned and redefining therapeutic paradigms","volume":"11","author":"Geng","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jphs.2022.05.004_bib2","doi-asserted-by":"crossref","first-page":"593021","DOI":"10.3389\/fphar.2021.593021","article-title":"Translational studies on anti-atrial fibrillatory action of oseltamivir by its in\u00a0vivo and in\u00a0vitro electropharmacological analyses","volume":"12","author":"Kambayashi","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jphs.2022.05.004_bib3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00210-004-0957-y","article-title":"Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels","volume":"370","author":"G\u00f6gelein","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.jphs.2022.05.004_bib4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/FJC.0b013e31824e1b93","article-title":"Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity","volume":"59","author":"Burashnikov","year":"2012","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jphs.2022.05.004_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1476-5381.1993.tb13448.x","article-title":"Antiarrhythmic agents act differently on the activation phase of the ACh-response in Guinea-pig atrial myocytes","volume":"108","author":"Inomata","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jphs.2022.05.004_bib6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.bjp.0702334","article-title":"Inhibitory effects of aprindine on the delayed rectifier K+ current and the muscarinic acetylcholine receptor-operated K+ current in Guinea-pig atrial cells","volume":"126","author":"Ohmoto-Sekine","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jphs.2022.05.004_bib7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0022-2828(85)80051-1","article-title":"Blockage of the sodium current in isolated single cells from rat ventricle with mexiletine and disopyramide","volume":"17","author":"Yatani","year":"1985","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.jphs.2022.05.004_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1253\/jcj.63.1","article-title":"Profiles of aprindine, cibenzoline, pilsicainide and pirmenol in the framework of the sicilian gambit. The guideline committee for Clinical use of antiarrhythmic drugs in Japan (working group of arrhythmias of the Japanese society of electrocardiology)","volume":"63","author":"Kodama","year":"1999","journal-title":"Jpn Circ J"},{"key":"10.1016\/j.jphs.2022.05.004_bib9","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.hrthm.2006.07.017","article-title":"Atrial-specific drug AVE0118 is free of torsades de pointes in anesthetized dogs with chronic complete atrioventricular block","volume":"3","author":"Oros","year":"2006","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jphs.2022.05.004_bib10","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s00380-020-01612-1","article-title":"Analysis of electropharmacological effects of AVE0118 on the atria of chronic atrioventricular block dogs: characterization of anti-atrial fibrillatory action by atrial repolarization-delaying agent","volume":"35","author":"Kambayashi","year":"2020","journal-title":"Heart Ves"},{"key":"10.1016\/j.jphs.2022.05.004_bib11","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1161\/01.CIR.0000143050.22291.2E","article-title":"\u201cEarly\u201d class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat","volume":"110","author":"Blaauw","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jphs.2022.05.004_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/cvr\/cvm051","article-title":"Changes in Ik,ACh single-channel activity with atrial tachycardia remodelling in canine atrial cardiomyocytes","volume":"77","author":"Voigt","year":"2008","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jphs.2022.05.004_bib13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/01.RES.81.4.512","article-title":"Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation","volume":"81","author":"Yue","year":"1997","journal-title":"Circ Res"},{"key":"10.1016\/j.jphs.2022.05.004_bib14","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1161\/01.RES.81.6.1045","article-title":"Tachycardia-induced changes in Na+ current in a chronic dog model of atrial fibrillation","volume":"81","author":"Gaspo","year":"1997","journal-title":"Circ Res"},{"key":"10.1016\/j.jphs.2022.05.004_bib15","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/bjp.2008.209","article-title":"Pathology-specific effects of the IKur\/Ito\/Ik,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation","volume":"154","author":"Christ","year":"2008","journal-title":"Br J Pharmacol"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861322000421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861322000421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:01:36Z","timestamp":1761163296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861322000421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1347861322000421"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2022.05.004","relation":{},"ISSN":["1347-8613"],"issn-type":[{"type":"print","value":"1347-8613"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Roles of IK,ACh for perpetuating atrial fibrillation: Effects of atrial-selective K+ channel inhibitor AVE0118 and class I drugs on the persistent atrial fibrillation canine model","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2022.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}